1. Home
  2. SOPH

as of 03-27-2026 3:35pm EST

$4.66
$0.07
-1.48%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Founded: 2011 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 367.7M IPO Year: 2021
Target Price: $7.00 AVG Volume (30 days): 100.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.58 - $5.70 Next Earning Date: 03-03-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 23.09% Revenue Growth (next year): 19.57%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered SOPH Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 62.58%
62.58%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)

Van Well Daan

Chief Legal Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.79

Shares

684

Total Value

$3,273.97

Owned After

261,238

SEC Form 4

Camblong Jurgi

Chief Executive Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.77

Shares

4,486

Total Value

$21,410.33

Owned After

3,302,839

SEC Form 4

Menu Philippe

Chief Medical Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.79

Shares

608

Total Value

$2,912.81

Owned After

173,616

SEC Form 4

Xu Zhenyu

Chief Scientific Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.78

Shares

608

Total Value

$2,907.03

Owned After

537,116

SEC Form 4

Valente Manuela

Chief People Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.79

Shares

380

Total Value

$1,818.34

Owned After

152,379

SEC Form 4

Muken Ross

President

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.79

Shares

1,183

Total Value

$5,670.95

Owned After

271,910

SEC Form 4

Puylaert Kevin

Chief Sales Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.76

Shares

33

Total Value

$157.08

Owned After

92,386

SEC Form 4

CARDOZA GEORGE

Chief Financial Officer

Sell
SOPH Mar 19, 2026

Avg Cost/Share

$4.79

Shares

774

Total Value

$3,704.52

Owned After

184,858

SEC Form 4

Share on Social Networks: